Skip to content
Research Article Open access CC BY 4.0

Design and Evaluation of a New Fixed-Dose Immediate Release Capsule of Atenolol, Enalapril Maleate and Hydrochlorothiazide

Nickania A. Pryce, Amusa S. Adebayo, Deon A. Bennett, Eugenie Brown-Myrie

Journal of Pharmaceutical Research International · pp. 1–16 · Published 4 Dec 2017

10.9734/JPRI/2017/38019

Abstract

Aim and Objectives: To design, formulate and perform in vitro studies of a fixed dose combination (FDC) immediate release solid dosage form of the antihypertensive drugs atenolol, enalapril and hydrochlorothiazide. The objectives of the study were to perform pre-formulation studies, design an immediate-release FDC capsule dosage form, and evaluate the prepared dosage form. Methods: Differential Scanning Calorimetric (DSC) analysis of physical mixtures of drugs and drug-excipient combinations was used to assess compatibility. Binary mixtures of atenolol and enalapril form a eutectic mixture indicating that a tablet dosage form, in which the drugs would be highly compressed together, may not be stable. Hard gelatin shell encapsulation was therefore employed. Atenolol and enalapril were separately dry-granulated with hydrochlorothiazide and excipients and mixed together at appropriate therapeutic proportions and encapsulated in size 1 hard gelatin capsules (HGC). Preliminary screening produced five formulations each with similar proportions of the 3-drug FDC but with 5 different levels of disintegrant. Capsule weight variation, disintegration time and dissolution rate were determined as output variables, following USP procedures. For the dissolution studies, a reverse phase high-pressure liquid chromatographic (RP-HPLC) method was developed for simultaneous analysis of the three drugs. Results: Granules possessed good fluidity (compressibility index 8.53 to 11.63 and tapped bulk density 1.09 to 1.132). Capsule disintegration time was generally £ 2 minutes while 80% of each drug dissolved within 20 minutes. Capsules showed no sign of physical instability or adverse effect during a period of 1 year shelf storage at room temperature (average temperature 25°C). Conclusions: Granules possess adequate fluidity and compressibility for filling into HGC. Results generally indicated that an immediate release FDC capsule of atenolol, enalapril and hydrochlorothiazide was stable for more than 1 year of observation. Capsule disintegration time and dissolution rate were generally within the USP specification.

Atenolol enalapril hydrochlorothiazide fixed-dose combination eutectic mixture.

References (15)

  1. 1 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure The JNC 7 Report [DOI]
  2. 2 Global atlas on cardiovascular disease prevention and control.
  3. 3 Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents [DOI]
  4. 4 Lippincott's Illustrated Reviews: Pharmacology
  5. 5 The United States Pharmacopoeia [DOI]
  6. 6 Definition and Classification of Hypertension: An Update [DOI]
  7. 7 Fixed dose drug combinations (FDCs): rational or irrational: a view point [DOI]
  8. 8 Low-Dose Quadruple Antihypertensive Combination [DOI]
  9. 9 IMMEDIATE DRUG RELEASE DOSAGE FORM: A REVIEW [DOI]
  10. 10 Simultaneous determination of enalapril maleate and hydrochlorothiazide by first-derivative ultraviolet spectrophotometry and high-performance liquid chromatography [DOI]
  11. 11 Development of a HPLC method for the simultaneous determination of losartan potassium and atenolol in tablets [DOI]
  12. 12 Optimization of mobile phase in the separation of β-blockers by HPLC [DOI]
  13. 13 Prescribing Patterns of fixed dose combinations in Hypertension,Diabetes Mellitus and Dyslipedimia among Patients attending a cardiology clinic in a tertiary care Teaching Hospital in India
  14. 14 Simultaneous estimation of atenolol, hydrochlorothiazide, losartan and valsartan in the pharmaceutical dosage form
  15. 15 Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. [DOI]

Cited by 1

Recent advancement over traditional drug in the treatment of hypertension

B. K. Yadav, Gopal L. Khatik, Jamshed Haneef · 2019

Related research

Article metrics

Real usage data collected on this platform.

73

Page views

0

PDF downloads

19

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.